Food for Thought: The Case for Two FDAs

Is it time to rethink the combination of food regulation with drugs and devices? One powerful member of Congress thinks so. The separation could be good for FDA, and maybe for biopharma companies too. But it is also a distraction at a bad time for the agency.

Are two agencies better than one? When it comes to the Food & Drug Administration, some key members of Congress—including the chair of the House Appropriations Subcommittee that controls FDA’s budget—think the answer is yes.

For the biotech and pharmaceutical industries, the last thing anyone wants to talk about is another overhaul at FDA. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet

Animal Testing: US And EU Regulatory Support Grows For Alternatives, But Validation A Hurdle

 

In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.

Senate Panel Approves US CDC Director Candidate Monarez With Measles Outbreak Growing

 
• By 

The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.

US FDA Advisory Committee Supports Vaccine Safety, Scrutinizes AE Reporting Quality

 
• By 

The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.